Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine (CC-486) Maintenance Therapy in Chinese Patients With Acute Myeloid Leukemia in Complete Remission
NCT05413018Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CC-486 in acute myeloid leukemia (AML), sponsored by Bristol Myers Squibb. Started Aug 2022; status: active, not recruiting.
02
Drugs
CC-486
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05413018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413018.